Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

• Main Authors: Camila Bezerra Melo Figueirêdo (Author), Joelma Rodrigues de Souza (Author), Daniel Handerson Galindo Soares (Author), Caio Cesar de Andrade Rodrigues Silva (Author), Virginia Maria Barros de Lorena (Author)
• Format: Book
• Published: Universidade de São Paulo, 2014-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), which targets the CD20 protein, present in over 8...